The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?

被引：7
|
作者：
Grant, S
机构：
[1] Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Dept Pharmacol, Richmond, VA 23298 USA
来源：
LEUKEMIA | 2004年 / 18卷 / 12期
关键词：
D O I：
10.1038/sj.leu.2403522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1931 / 1933
页数：3
相关论文
共 50 条
  • [31] Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma
    Kato, Yukihiko
    Salumbides, Brenda C.
    Wang, Xiao-Fei
    Qian, David Z.
    Williams, Simon
    Wei, Yongfeng
    Sanni, Tolib B.
    Atadja, Peter
    Pili, Roberto
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (01) : 70 - 81
  • [32] Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma
    Zafar, Syed F.
    Nagaraju, Ganji Purnachandra
    El-Rayes, Bassel
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (07) : 707 - 718
  • [33] PS341 (Bortezomib) and the histone deacetylase inhibitor LAQ824 sensitize Melphalan resistant Multiple Myeloma cells to Melphalan.
    Sonneveld, P
    van Oostrum, NHM
    Schoester, M
    van Oosterhoud, S
    BLOOD, 2003, 102 (11) : 189A - 190A
  • [34] The lethality of the histone deacetylase inhibitors SAHA and NVP-LAQ824 is enhanced by interrupting NF-kappaB activation through a mechanism involving inhibition of IKK-mediated RelA/p65 phosphorylation (serine 536) in human multiple myeloma cells
    Dai, Yun
    Hamm, Tracy
    Chen, Shuang
    Dent, Paul
    Grant, Steven
    CANCER RESEARCH, 2006, 66 (08)
  • [35] Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells
    Hurtubise, Annie
    Momparler, Richard L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (05) : 618 - 625
  • [36] Effective induction of apoptosis in chronic myeloid leukemia CD34+cells by the historic deacetylase inhibitor LAQ824 in combination with imatinib
    Strauss, Adam C.
    Chu, So
    Holyoake, Tessa
    Bhatia, Ravi
    BLOOD, 2007, 110 (11) : 312A - 312A
  • [37] Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin A
    Huong Thi Thanh Tran
    Kim, Hee Nam
    Lee, Il-Kwon
    Thanh-Nhan Nguyen-Pham
    Ahn, Jae-Sook
    Kim, Yeo-Kyeoung
    Lee, Je-Jung
    Park, Kyeong-Soo
    Kook, Hoon
    Kim, Hyeoung-Joon
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (02) : 237 - 246
  • [38] Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
    Warrell, RP
    He, LZ
    Richon, V
    Calleja, E
    Pandolfi, PP
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (21): : 1621 - 1625
  • [39] Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells
    Annie Hurtubise
    Richard L. Momparler
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 618 - 625
  • [40] Characterization of the apoptotic and therapeutic activities of the histone deacetylase inhibitors LAQ824 and LBH589 using a mouse model of B cell lymphoma
    Ellis, Leigh
    Lindemann, Ralph
    Newbold, Andrea
    Whitecross, Kate
    Cluse, Leonie
    Pelligrini, Marc
    Wei, Andrew
    Scott, Clare
    Atadja, Peter
    Lowe, Scott
    Johnstone, Ricky W.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3475S - 3476S
12345